Strong execution meets street skepticism: the 29% gap from ATH tells the real story
Revenue jumped 22.2%, PAT surged 29.5%, and margins expanded 100 basis points. Management raised guidance and sustained large deal momentum. Yet FII flows are turning negative, and the stock trades 29% below its all-time high. The market is pricing in execution risk on the path to 14–15% EBIT margins.
₹232 Cr
+29.5% YoY, 8.2% NPM
12.5%
+100 bps YoY, in-band (12.25–12.75%)
12.3%
Supports full-year 10.5–13% band
The delivered story
Firstsource delivered a strong Q2: revenue ₹2,826 Cr (22.2% YoY), net profit ₹232 Cr (29.5% YoY), and EBIT margin 12.5%, up 100 basis points year-over-year. The quarter reinforces the company's three-year arc — moving from labor-arbitrage services toward AI-enabled, productized delivery. Management raised the FY27 constant-currency revenue guidance lower bound from 10% to 10.5%, and reaffirmed the EBIT margin band at 12.25–12.75% despite wage hikes (~3%) and 3,062 net headcount additions. Margin expansion in the face of cost inflation signals operational leverage and productivity gains offsetting wage pressures. For now, the numbers support the narrative.
What holds up, what carries risk
Large deal momentum sustained (4 in Q2, 7th straight quarter)
51 clients >$5M run rate (+6 QoQ, largest Q2 gain in 5 quarters). 17 new logos in Q2, one of the highest quarterly adds. Customer wallet deepening evident.
Supported
EBIT margin expansion despite cost headwinds
12.5% margin in Q2, +100 bps YoY and +10 bps QoQ, despite 3% wage hikes and 3,062 net hiring (85% offshore/nearshore). Margin in-band (12.25–12.75%).
Supported
Healthcare segment transitioning to AI-enabled models, not contracting
Healthcare 5% YoY growth but 2% decline QoQ in CC. 4 new logos added Q2. Management flagged HR1 expansion (Jan 2027) and denials AI platform as recovery drivers for H2.
Plausible but execution-dependent
Path to 14–15% EBIT margin in 2–3 years; 50–75 bps annual improvement expected
Q2 base is 12.5%. Mechanism depends on productization >50% of revenues (Kairos platform ramping but not yet fully capitalized). Second-implementation economics stronger, but scale unproven.
Plausible but contingent on Kairos ramp
What changed on this call
The street's view: why down 29% from ATH despite strong Q2?
Firstsource trades at ₹292.9, down 29% from its all-time high of ₹413.3. The stock is above its 20-day, 50-day, and 200-day moving averages (bullish trend), but that ATH gap is stark given a 22% revenue quarter, margin expansion, and raised guidance. The ownership picture explains some of that caution: FII holdings have shrunk from 10.08% a year ago to 8.38%, a 170-basis-point outflow. DII ownership is steady at 25.41% (up slightly from 22.90% a year prior), and promoters remain locked at 53.66%. Foreign institutional flows turning negative despite strong Q2 results suggest the street is pricing in execution risk — either on the sustainability of 4+ large deals per quarter in a macro backdrop with visible headwinds (deal value compression, decision-cycle elongation flagged on the call), or on the productization story and the path to 14–15% EBIT.
Bull-bear ledger
22.2% revenue growth, 29.5% PAT growth, 100 bps EBIT margin expansion all in one quarter
4th large deal in Q2; 7 consecutive quarters of 4+ large wins signals repeatable sales model
51 clients >$5M, 23 clients >$10M; customer concentration risk easing as wallet deepens
FY27 guidance lower end raised (10% → 10.5%); management backing raised floor with execution credibility
FCF to PAT 150% (Q2), 126% (H1); cash generation strong, working capital discipline evident
Healthcare segment contracting QoQ (2% decline CC) despite 5% YoY; transition risk is real
Large deal sustainability unproven beyond 7 quarters; macro headwinds (deal values shrinking, cycles elongating) flagged on call
Productization revenue (>50%) not yet translating to step-function margin uplift; Kairos still ramping, not fully capitalized
14–15% EBIT target in 2–3 years is bold; depends entirely on execution of productization and sustained large deal wins
FII outflows (−170 bps YoY) despite strong results signal institutional caution on execution risk
Risks, ranked by holder concern
Healthcare vertical transition timing and success
MediumQ2 showed 5% YoY growth but 2% decline QoQ CC. Management flagged HR1 expansion (Jan 2027) and denials AI as drivers of H2 recovery, but that's a 6-month optionality, not a given. If H2 healthcare remains flat or negative QoQ, the largest vertical's growth trajectory breaks. With 4 new logos added Q2, management is confident, but adoption and deal closure timing in the US payer/provider market are execution-dependent.
Large deal momentum dependency and macro headwinds
Medium7 consecutive quarters of 4+ large deals is impressive, but analysts pressed management on sustainability. Call Q&A flagged macro pressure: deal values potentially shrinking, decision cycles elongating. If large deal closures slow to 3/quarter or values compress, FY27 lower-end guidance (10.5% CC growth) becomes at risk. Top 5 clients remain at 22+ years tenure and growing at 'industry rate,' but one major loss could upend trajectory.
Productization execution and 14–15% EBIT target credibility
MediumManagement targets 14–15% EBIT in 2–3 years (vs. 12.5% Q2 base). Mechanism depends on productization revenue >50% of total (claimed), with Kairos platform at scale. However, Kairos is not yet fully capitalized; costs are being absorbed into EBIT today. Second-implementation economics are better, but the margin step-function from 12.5% to 14.5% is contingent on Kairos reaching revenue scale AND productization >60%. If Kairos ramp slows or productization stalls below 55%, the long-term target becomes unrealistic, and EBIT guidance could reset lower.
Wage inflation and cost absorption capacity
LowManagement absorbed ~3% wage hikes Q2 and still expanded margins 100 bps YoY. Onshoring/nearshore hiring (85% India/Philippines) provides cost leverage. But if wage inflation accelerates beyond 3% or hiring pace overshoots (burnout, turnover), margin guidance could face pressure. EBIT headcount plan for Q3 'reflects wage increments,' so management is ahead of it for now.
Top 5 client concentration and loss
Low51 clients >$5M and 23 clients >$10M suggest portfolio broadening, but top 5 still represent material revenue. While tenured relationships (22+ years avg) are sticky, loss of one top-5 client would ripple through growth. Large deal pipeline and new logos (+17 Q2) provide some buffer, but this remains a structural concentration risk.
Management quality and credibility
Ritesh Idnani (MD & CEO) and team conveyed confidence on strategy (services → productization) and portfolio strength (large deals, customer wallet deepening). They were transparent on challenges: healthcare transition, macro headwinds on deal values and cycles. When pressed on large deal sustainability (can 4 become 6 per quarter?), they framed it as sales org reshaping and pipeline visibility backing the 4+ cadence. Wage hike quantification deferred offline; Kairos capex number not disclosed. These omissions limit real-time granularity but don't undermine overall credibility. Track record is solid: raised FY27 lower-end guidance (10% → 10.5%) backed by H1 delivery (12.3% CC), and maintained EBIT band despite cost pressures. Tone confident but measured; not hyper-bullish. Overall management score 7/10 — credible execution with acknowledged execution dependencies.
The debate
What to watch next
1 · Healthcare segment sequential growth (H2 FY27 result)
Will healthcare stabilize and return to sequential growth in Q3 FY27? HR1 expansion (Jan 2027) and denials AI scale are flagged recovery drivers. If H2 shows healthcare >0% sequential CC growth, the transition narrative gains credibility and risk profile drops materially. If flat or negative again, execution risk on healthcare AI pivot becomes critical.
2 · Large deal win cadence (quarterly through Q4 FY27)
Can management sustain 4+ large deals per quarter, or will macro headwinds (deal value compression, cycle elongation) pull it down to 3 or fewer? Sales org reshape and pipeline visibility are management's levers. This is the macro-sensitivity test. If wins sustain, upper-end guidance (13% CC revenue growth) becomes credible.
3 · Productization revenue inflection (Q3/Q4 FY27 and Q1 FY28)
Will productization cross 55–60% of revenues and show demonstrable margin uplift (EBIT >12.75%)? Kairos ramp, second-implementation economics, and platform scale are the proof points. If productization stalls below 52%, the 14–15% EBIT target timeline will extend, and guidance may reset.
The number to track
EBIT margin progression. Current base: 12.5% (Q2 FY27). Management's guided band: 12.25–12.75%. Watch for sustained expansion into Q3 and Q4 FY27, with target end-of-year >12.75%. If FY27 closes at 12.75% EBIT and management guides 50–75 bps annual improvement through FY28–FY29, the 14–15% target becomes a credible 3-year thesis. If Q3/Q4 EBIT margin contracts or stays flat, the path to 14–15% either extends or resets lower.
Firstsource delivered a strong Q2 with genuine operational progress: margin expansion despite cost headwinds, large deal momentum sustained, and customer concentration easing. The company raised FY27 guidance on credible execution. But the street's caution (FII outflows, stock down 29% from ATH) is not irrational — it's a bet that either healthcare's AI transition will stumble, large deals will compress in a macro downturn, or productization execution will fall short of the 14–15% EBIT target in 2–3 years.
This is steady execution, not a step-change. Hold until H2 FY27 delivers proof on healthcare stabilization, large deal sustainability, or productization revenue crossing 55%+ with visible margin uplift. If any one of those conditions breaks, the Hold case upgrades. If all three hold, 14–15% EBIT becomes credible and the stock re-rates higher.
Informational and educational content only. Not investment advice.